SCHEMBL4296174

SCHEMBL4296174

Cc1csc2c(=O)n(-c3ccc(OC(F)(F)F)cc3)c(CC(C)C(F)(F)F)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GRM1 Q13255 3/20 0.40
MALT1 Q9UDY8 1/20 0.38
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
NPBWR1 P48145 2/20 0.35
MCHR1 Q99705 2/20 0.35
TRPV4 Q9HBA0 4/20 0.35
TDP2 O95551 1/20 0.34
CRHR1 P34998 1/20 0.33
KCNH2 Q12809 1/20 0.33
GPR139 Q6DWJ6 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
GRM5 P41594 1/20 0.33
NR1H4 Q96RI1 1/20 0.32
HPD P32754 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4980646 0.88 KDM4E (0.37) POLBGRM1KDM4EMAPK1GRM5
SCHEMBL4516570 0.69 POLB (0.41) POLBGRM1MAPTMAPK1GRM5
SCHEMBL4083046 0.66 POLB (0.46) POLBGRM1MAPTGRM5
SCHEMBL4523280 0.64 POLB (0.40) POLBGRM1KDM4EGRM5
SCHEMBL4515956 0.64 POLB (0.40) POLBGRM1MALT1KDM4EGRM5
SCHEMBL2237018 0.63 GRM1 (0.40) L3MBTL1GRM1MALT1KDM4EMAPT
SCHEMBL4978894 0.63 DRD1 (0.44) POLBGRM1KDM4E
SCHEMBL4427546 0.63 DRD1 (0.44) POLBGRM1KDM4E
SCHEMBL4427544 0.63 DRD1 (0.44) POLBGRM1KDM4E
SCHEMBL11908071 0.63 GRM1 (0.40) POLBGRM1MALT1KDM4ETRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061470-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-05-27 EP claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 POLB 2214/4885L3MBTL1 3098/4885GRM1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.